126 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28523115	59	Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP	Novartis Institutes For Biomedical Research
28169162	86	Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist.	Askat
27133594	6	Piperidine derivatives as nonprostanoid IP receptor agonists 2.	Toray Industries
26996371	27	Piperidine derivatives as nonprostanoid IP receptor agonists.	Toray Industries
26061158	136	A selective prostaglandin E2 receptor subtype 2 (EP2) antagonist increases the macrophage-mediated clearance of amyloid-beta plaques.	Amgen
25127105	4	Evaluation of the cyclopentane-1,2-dione as a potential bio-isostere of the carboxylic acid functional group.	University of Pennsylvania
25241924	47	The design and implementation of a generic lipopeptide scanning platform to enable the identification of 'locally acting' agonists for the apelin receptor.	Novartis Institutes For Biomedical Research
25221659	13	Potent, long-acting cyclopentane-1,3-Dione thromboxane (A2)-receptor antagonists.	University of Pennsylvania
24512187	69	Discovery of isoquinolinone indole acetic acids as antagonists of chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2) for the treatment of allergic inflammatory diseases.	Pfizer
24252546	9	SAR-based optimization of 2-(1H-pyrazol-1-yl)-thiazole derivatives as highly potent EP1 receptor antagonists.	Asahi Kasei Pharma
24021582	52	Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases.	Novartis Institutes For Biomedical Research
23688698	68	Synthesis and pharmacological evaluation of 2-aryloxy/arylamino-5-cyanobenzenesulfonylureas as novel thromboxane A2 receptor antagonists.	University of Liege
23324405	49	Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffold.	Actelion Pharmaceuticals
23721423	144	Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist.	Actelion Pharmaceuticals
17098427	34	1,5-Biaryl pyrrole derivatives as EP1 receptor antagonists: Structure-activity relationships of 4- and 5-substituted benzoic acid derivatives.	Glaxosmithkline
17175160	32	1,5-Biaryl pyrrole derivatives as EP1 receptor antagonists. Structure-activity relationships of 6-substituted and 5,6-disubstituted benzoic acid derivatives.	Glaxosmithkline
9016331	6	Synthesis and evaluation of trimetoquinol derivatives: novel thromboxane A2/prostaglandin H2 antagonists with diminished beta-adrenergic agonist activity.	Ohio State University
1346651	29	Synthesis of halogenated trimetoquinol derivatives and evaluation of their beta-agonist and thromboxane A2 (TXA2) antagonist activities.	Ohio State University
	56	Novel prostanoid thromboxane A2 antagonists	TBA
	31	New TXA2/PGH2 receptor antagonists based on the carbacyclin skeleton	TBA
	43	Synthesis and pharmacological evaluation of combined Thromboxane receptor antagonists/thromboxane synthase inhibitors: Pyridine-containing amino-prostanoids	TBA
22651823	57	Diazine indole acetic acids as potent, selective, and orally bioavailable antagonists of chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2) for the treatment of allergic inflammatory diseases.	Pfizer
22931505	69	Chemokine receptor antagonists.	National Heart and Lung Institute
22224640	53	Update on the development of antagonists of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). From lead optimization to clinical proof-of-concept in asthma and allergic rhinitis.	Oxagen
22726929	118	Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.	Actelion Pharmaceuticals
19804971	63	Discovery and optimization of CRTH2 and DP dual antagonists.	Amgen
18359630	37	Identification of prostaglandin D2 receptor antagonists based on a tetrahydropyridoindole scaffold.	Merck Frosst Canada
18291643	76	Structure-activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP(4) receptor.	Merck Frosst Centre For Therapeutic Research
16931013	138	Comparison between two classes of selective EP(3) antagonists and their biological activities.	Merck Frosst Centre For Therapeutic Research
16220969	219	Designed multiple ligands. An emerging drug discovery paradigm.	Organon Laboratories
15914004	34	Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3.	Fujisawa Pharmaceutical
1826745	4	Novel synthesis and biochemical properties of an [125I]-labeled photoaffinity probe for thromboxane A2/prostaglandin H2 receptors.	Eli Lilly
12643927	164	Discovery of a potent and selective agonist of the prostaglandin EP4 receptor.	Merck Frosst Centre For Therapeutic Research
21958540	95	Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.	Amira Pharmaceuticals
21906954	2	Searching for new NO-donor aspirin-like molecules: Furoxanylacyl derivatives of salicylic acid and related furazans.	Universit£
21863799	44	Cyclopentane-1,3-dione: a novel isostere for the carboxylic acid functional group. Application to the design of potent thromboxane (A2) receptor antagonists.	University of Pennsylvania
21885288	109	Design and synthesis of new prostaglandin D2 receptor antagonists.	Minase Research Institute
21737285	138	Discovery of selective indole-based prostaglandin D2 receptor antagonist.	Minase Research Institute
20615693	37	Tricyclic imidazole antagonists of the Neuropeptide S Receptor.	Merck Research Laboratories
21515053	58	New indole amide derivatives as potent CRTH2 receptor antagonists.	Merck Frosst
21211969	42	Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist.	Amira Pharmaceuticals
21106375	198	Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.	Merck Frosst Centre For Therapeutic Research
21208803	81	The identification of substituted benzothiophene derivatives as PGE(2) subtype 4 receptor antagonists: From acid to non-acid.	Merck Frosst Centre For Therapeutic Research
21185722	74	Azaindoles as potent CRTH2 receptor antagonists.	Merck Frosst Centre For Therapeutic Research
21036609	38	Potent and highly selective DP1 antagonists with 2,3,4,9-tetrahydro-1H-carbazole as pharmacophore.	Merck Frosst Centre For Therapeutic Research
20926294	65	3-Urea-1-(phenylmethyl)-pyridones as novel, potent, and selective EP3 receptor antagonists.	Glaxosmithkline
20813948	63	Spiroindolones, a potent compound class for the treatment of malaria.	Swiss Tropical and Public Health Institute
20591666	66	A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.	Università
20471829	43	Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain.	Merck Frosst Canada
20457519	29	3-Indolyl sultams as selective CRTh2 antagonists.	Athersys
20137942	39	Exploration of SAR features by modifications of thiazoleacetic acids as CRTH2 antagonists.	7Tm Pharma
20163116	116	The discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist.	Merck Frosst Centre For Therapeutic Research
19608418	95	Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.	Amira Pharmaceuticals
19592244	61	7-Azaindole-3-acetic acid derivatives: potent and selective CRTh2 receptor antagonists.	Novartis Institutes of Biomedical Research
19487124	39	Discovery of novel aminothiadiazole amides as selective EP(3) receptor antagonists.	Glaxosmithkline
8496700	16	The Role of Receptor Binding in Drug Discovery	TBA
	2	Synthesis of a fluorescent labeled thromboxane A2 receptor antagonist	TBA
	6	Synthesis of a novel series of 3-oxo-2,4-dioxobicyclo[3.2.1]octanes: additional evidence for two thromboxane receptor subtypes.	TBA
	16	Oxa-prostanoid analogs. Identification of an orally effective, dual thromboxane receptor antagonist /thromboxane synthase inhibitor	TBA
	24	Thia-prostanoid analogs with combined thromboxane receptor antagonist/thromboxane synthase inhibitor activities. Synthesis and pharmacological evaluation	TBA
	6	Thoromboxane A2/endoperoxide receptor antagonists: 1,3-Dioxane and 1,3-dioxolane analogs	TBA
	6	Syntheses of Cyclopentane, Cyclohexene and Olefin Oxazoles as Thromboxane A2/Endoperoxide Receptor Antagonists	TBA
	2	Synthesis of pyrrolidine oxazoles as thromboxane A2/endoperoxide receptor antagonists	TBA
	2	Interphenylene phenyl oxazoles: novel, potent thromboxane receptor antagonists	TBA
	1	Interphenylene 7-oxabicyclo[2.2.1]heptanes. SQ33,961: a new potent, long-acting thromboxane antagonist	TBA
	5	Structural homologies among thromboxane (TXA2) receptor antagonists: Minimal pharmacophoric requirements for high affinity interaction with TXA2 receptors	TBA
19332369	43	Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate (GSK269984A) an EP(1) receptor antagonist for the treatment of inflammatory pain.	Glaxosmithkline
19307115	89	Discovery of potent and selective DP1 receptor antagonists in the azaindole series.	Merck Frosst Centre For Therapeutic Research
19036582	45	Discovery of GSK345931A: An EP(1) receptor antagonist with efficacy in preclinical models of inflammatory pain.	Glaxosmithkline
18701276	97	Highly functionalized 7-azaindoles as selective PPAR gamma modulators.	Merck Research Laboratories
17630727	76	Design, synthesis, and SAR study of a series of N-alkyl-N'-[2-(aryloxy)-5-nitrobenzenesulfonyl]ureas and -cyanoguanidine as selective antagonists of the TPalpha and TPbeta isoforms of the human thromboxane A2 receptor.	University of LièGe
17531480	51	2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists.	Novartis Institutes of Biomedical Research
17300164	62	Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).	Merck Frosst Canada
16759113	75	Synthesis and pharmacological evaluation of novel nitrobenzenic thromboxane modulators as antiplatelet agents acting on both the alpha and beta isoforms of the human thromboxane receptor.	University of LièGe
16529930	96	Identification of an indole series of prostaglandin D2 receptor antagonists.	Merck Frosst Canada
16078846	40	Development of dual-acting benzofurans for thromboxane A2 receptor antagonist and prostacyclin receptor agonist: synthesis, structure-activity relationship, and evaluation of benzofuran derivatives.	Toray Industries
15935659	17	Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4.	Fujisawa Pharmaceutical
15857112	55	Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists.	Fujisawa Pharmaceutical
15745833	55	Isosteric ramatroban analogs: selective and potent CRTH-2 antagonists.	Athersys
15715457	30	Minor structural modifications convert the dual TP/CRTH2 antagonist ramatroban into a highly selective and potent CRTH2 antagonist.	7Tm Pharma
15686932	36	2,3-Diarylthiophenes as selective EP1 receptor antagonists.	Merck Frosst Centre For Therapeutic Research
15149674	57	Benzimidazoles as new potent and selective DP antagonists for the treatment of allergic rhinitis.	Merck Frosst Centre For Therapeutic Research
14552786	88	Structure-activity relationship of triaryl propionic acid analogues on the human EP3 prostanoid receptor.	Merck Frosst Centre For Therapeutic Research
11708917	33	Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis.	Procter & Gamble Pharmaceuticals
11327579	3	Structure determination and comparison of BM567, a sulfonylurea, with terbogrel, two compounds with dual action, thromboxane receptor antagonism and thromboxane synthase inhibition.	FacultéS Universitaires N.D. De La Paix
11266183	32	Structure-activity relationship on the human EP3 prostanoid receptor by use of solid-support chemistry.	Merck Frosst Canada
10915040	84	Synthesis and in vitro evaluation of human FP-receptor selective prostaglandin analogues.	Procter & Gamble Pharmaceuticals
10715159	112	Design and synthesis of 13,14-dihydro prostaglandin F(1alpha) analogues as potent and selective ligands for the human FP receptor.	Procter and Gamble Pharmaceuticals
10571156	1	Synthesis and biological characterization of sqbazide, a novel biotinylated photoaffinity probe for the study of the human platelet thromboxane A2 receptor.	Ecole Nationale SupéRieure De Chimie De Paris
10509919	103	New class of biphenylene dibenzazocinones as potent ligands for the human EP1 prostanoid receptor.	Merck Frosst Centre For Therapeutic Research
10197967	70	Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.	Boehringer Ingelheim Pharma
10091692	44	Synthesis and thromboxane A2 antagonistic activity activity of indane derivatives.	Zeria Pharmaceutical
9876106	49	Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 3. Synthesis and biological activities of oxazolecarboxamide-substituted omega-phenyl-omega-(3-pyridyl)alkenoic acid derivatives and related compounds.	Eli Lilly
9873463	39	Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 2. Design, synthesis, and evaluation of a novel series of phenyl oxazole derivatives.	Eli Lilly
9357516	94	Bicyclo[2.2.1]heptane and 6,6-dimethylbicyclo[3.1.1]heptane derivatives: orally active, potent, and selective prostaglandin D2 receptor antagonists.	Shionogi
8831771	64	On the bioisosteric potential of diazines: diazine analogues of the combined thromboxane A2 receptor antagonist and synthetase inhibitor Ridogrel.	University of Innsbruck
8496908	39	Interphenylene 7-oxabicyclo[2.2.1]heptane oxazoles. Highly potent, selective, and long-acting thromboxane A2 receptor antagonists.	Bristol-Myers Squibb Pharmaceutical Research Institute
8487256	33	Synthesis and structure-activity relationships of novel benzimidazole and imidazo[4,5-b]pyridine acid derivatives as thromboxane A2 receptor antagonists.	Carpibem
8289199	105	6,6-Disubstituted Hex-5-enoic acid derivatives as combined thromboxane A2 receptor antagonists and synthetase inhibitors.	Dr. Karl Thomae
7932586	102	Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.	Pharmacia-Farmitalia Carlo Erba
8809159	26	Iodinated analogs of trimetoquinol as highly potent and selective beta 2-adrenoceptor ligands.	University of Tennessee-Memphis
29636218	43	Discovery of {4-[4,9-bis(ethyloxy)-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-2-fluorophenyl}acetic acid (GSK726701A), a novel EP	Glaxosmithkline
2769691	4	Quinones. 4. Novel eicosanoid antagonists: synthesis and pharmacological evaluation.	Takeda Chemical Industries
2523485	5	9,11-Epoxy-9-homo-14-thiaprost-5-enoic acid derivatives: potent thromboxane A2 antagonists.	Squibb Institute For Medical Research
2391688	9	7-Oxabicyclo[2.2.1]heptyl carboxylic acids as thromboxane A2 antagonists: aza omega-chain analogues.	Squibb Institute For Medical Research
1910091	7	Interphenylene 7-oxabicyclo[2.2.1]heptane thromboxane A2 antagonists. Semicarbazone omega-chains.	Bristol-Myers Squibb Pharmaceutical Research Institute
1535377	5	Synthesis and thromboxane A2/prostaglandin H2 receptor antagonistic activity of phenol derivatives.	Takeda Chemical Industries
1501231	1	PgH2 analogs as potential antiplatelet derivatives.	University of Illinois
1388208	45	Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 2.	Kyowa Hakko Kogyo
1388207	72	Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1.	Kyowa Hakko Kogyo
26469307	7	Phosphorylation of Capsaicinoid Derivatives Provides Highly Potent and Selective Inhibitors of the Transcription Factor STAT5b.	University of Leipzig